Loading
ReadUpdated Jul 4, 2026
Analysis
Source-backed trade-policy analysis for import-scope decisions. Start from a product line, origin, supplier, or case, then move from public record to operating posture.
Published pieces71 in the archive
Current leadOrigin decision support
Evidence standardCitable public records
Primary useImport-team framing
Browse
Topics
Origin review11 piecesUSMCA reviewAuto rules of origin+1Entry posture review18 piecesRefund postureCAPE processing+3Trade policy4 piecesPolicy monitoringMetals scope review3 piecesSection 232 metalsSection 232 copper+1Trade remedies3 piecesAD/CVD ordersPhosphate CVD ordersExport controls5 piecesLicensing regimeFDPR enforcement+1Tariff authority20 piecesSection 301 trackSection 122 surcharge+2Customs enforcement3 piecesUFLPA enforcementDe minimis administrationTrade governance3 piecesAdvisory committeeEXIM reauthorization+1
Filtered
Tariff authority stream
Section 232 Is the Pharma Tariff. Drug-Pricing Section 301 Is the Record-Building Track.
Not yet a Section 301 tariff. USTR has opened the drug-pricing record, but the live duty exposure remains Proclamation 11020's Section 232 regime.
The EU Made Its Turnberry Tariff Cuts Reversible, and the Trigger Dates Now Govern the Deal
Parliament approved the EU side of Turnberry on June 16, 2026, but built the cuts to be reversible, so a calendar of EU suspension triggers governs the deal.
The EU Approved Its Half of Turnberry, and the U.S. 15 Percent Ceiling Has Already Fragmented
The European Parliament approved the EU side of the Turnberry framework on June 16, 2026, but the United States 15 percent ceiling it was bargained against no longer runs on a single statute. After the Supreme Court struck down the IEEPA tariffs, the commitment survives unevenly across a temporary Section 122 surcharge, Section 232 sector tariffs, and a proposed Section 301 forced-labor track, so EU-origin importers are now planning against a patchwork rather than a clean 15 percent cap.
